Inovio's ino-5401 in combination with pd-1 inhibitor libtayo® (cemiplimab) demonstrates 85% of newly diagnosed glioblastoma patients are alive 12 months following treatment

Plymouth meeting, pa., may 14, 2020 /prnewswire/ -- inovio (nasdaq: ino) today announced that 85 percent (44 out of 52) of patients newly diagnosed with the deadly brain cancer glioblastoma multiforme (gbm) who received the company's dna medicine ino-5401, in combination with ino-9012 and...

INO Ratings Summary

INO Quant Ranking